Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 4Thoracic 3Dermatologic 2Plasma cell 1Genitourinary 1

Conditions

Melanoma 2

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Tretinoin × Dermatologic × Clear all
NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 1/2 Completed
26 enrolled 13 charts
Dermatologic

Melanoma

NCT02403778 2023-09-21

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 2 Completed
10 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡